These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29036806)

  • 1. Pritumumab, the first therapeutic antibody for glioma patients.
    Babic I; Nurmemmedov E; Yenugonda VM; Juarez T; Nomura N; Pingle SC; Glassy MC; Kesari S
    Hum Antibodies; 2018 Feb; 26(2):95-101. PubMed ID: 29036806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab.
    Glassy MC; Hagiwara H
    Hum Antibodies; 2009; 18(4):127-37. PubMed ID: 19996527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unconventional immunotherapy with an unconventional target.
    Glassy MC
    Hum Antibodies; 2020; 28(4):253-258. PubMed ID: 32925025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients].
    Kubo O; Takakura K
    Nihon Rinsho; 2002 Mar; 60(3):497-503. PubMed ID: 11904965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Binding Potency Assay for Pritumumab and Ecto-Domain Vimentin.
    Babic I; Kesari S; Glassy MC
    Methods Mol Biol; 2019; 1904():401-415. PubMed ID: 30539482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen related to cell proliferation in malignant gliomas recognized by a human monoclonal antibody.
    Kokunai T; Tamaki N; Matsumoto S
    J Neurosurg; 1990 Dec; 73(6):901-8. PubMed ID: 2230972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models.
    Shoji T; Saito R; Chonan M; Shibahara I; Sato A; Kanamori M; Sonoda Y; Kondo T; Ishii N; Tominaga T
    Neuro Oncol; 2016 Aug; 18(8):1120-8. PubMed ID: 26917236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-TA226 human monoclonal antibody (ACA-11) against glioma].
    Kokunai T
    Nihon Rinsho; 2002 Jan; 60(1):100-6. PubMed ID: 11808318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
    Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
    Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning.
    Iizuka A; Komiyama M; Oshita C; Kume A; Ashizawa T; Mitsuya K; Hayashi N; Nakasu Y; Yamaguchi K; Akiyama Y
    Immunol Lett; 2014; 159(1-2):15-22. PubMed ID: 24534640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy in brain tumors].
    De Carli E; Delion M; Rousseau A
    Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell- and peptide-based immunotherapeutic approaches for glioma.
    Yamanaka R
    Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in gliomas: Are we reckoning without the innate immunity?
    Vismara MFM; Donato A; Malara N; Presta I; Donato G
    Int J Immunopathol Pharmacol; 2019; 33():2058738419843378. PubMed ID: 30968718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy.
    Hugwil AV
    Med Hypotheses; 2013 Sep; 81(3):489-95. PubMed ID: 23856243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
    Zhang C; Li J; Wang H; Song SW
    Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of brain tumors.
    Sawamura Y; De Tribolet N
    J Neurosurg Sci; 1990; 34(3-4):265-78. PubMed ID: 2098505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody therapy for malignant glioma.
    Chen KS; Mitchell DA
    Adv Exp Med Biol; 2012; 746():121-41. PubMed ID: 22639164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
    Yajima N; Yamanaka R; Mine T; Tsuchiya N; Homma J; Sano M; Kuramoto T; Obata Y; Komatsu N; Arima Y; Yamada A; Shigemori M; Itoh K; Tanaka R
    Clin Cancer Res; 2005 Aug; 11(16):5900-11. PubMed ID: 16115932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T11TS immunotherapy repairs PI3K-AKT signaling in T-cells: Clues toward enhanced T-cell survival in rat glioma model.
    Chaudhuri S; Singh MK; Bhattacharya D; Datta A; Hazra I; Mondal S; Faruk Sk Md O; Ronsard L; Ghosh TK; Chaudhuri S
    J Cell Physiol; 2018 Feb; 233(2):759-770. PubMed ID: 28608562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the antigen/epitope that is recognized by human monoclonal antibody CLN-IgG.
    Hagiwara H; Aotsuka Y; Yamamoto Y; Miyahara J; Mitoh Y
    Hum Antibodies; 2001; 10(2):77-82. PubMed ID: 11673662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.